ALAMEDA, Calif., August 6, 2026
Vivani Medical, Inc. announced the successful full enrollment and initial dosing of all 20 participants in its SLIM-1™ Phase 1 clinical trial evaluating NPM-139, a miniature, ultra long-acting subdermal semaglutide implant designed for chronic weight management. The milestone was achieved ahead of schedule, with the first 10 participants dosed on July 29 and the remaining participants treated one week later. According to the company, all implant insertion procedures were completed successfully without complications, marking an important step in advancing its proprietary NanoPortal™ drug delivery platform. The randomized, active-controlled study compares NPM-139 with Wegovy® (semaglutide injection) to evaluate safety, tolerability, pharmacokinetics, and changes in body weight, with top-line results expected in November 2026..
NanoPortal Implant Aims to Improve Long-Term GLP-1 Therapy
NPM-139 is designed to provide continuous semaglutide delivery for six to twelve months through a single miniature subdermal implant, potentially overcoming adherence challenges associated with weekly injections. The SLIM-1 trial enrolls 20 GLP-1 treatment-naïve overweight or obese adults in Australia, with 10 participants receiving low-dose NPM-139 and 10 receiving the standard starting dose of Wegovy (0.25 mg weekly) over a four-week evaluation period. The primary objectives include assessing safety, tolerability, and pharmacokinetic performance, while monitoring changes in body weight. Unlike conventional injectable GLP-1 therapies, NanoPortal technology is engineered to maintain steady drug exposure for extended periods while allowing rapid implant removal if treatment discontinuation becomes necessary, an important feature for situations such as pregnancy or planned surgery where GLP-1 therapy may need to be stopped quickly..
Preclinical Success and Strategic Collaboration Support Development
The advancement of SLIM-1 follows encouraging preclinical studies, in which NPM-139 demonstrated sustained body weight reductions of approximately 20% in animal models, supporting further clinical evaluation. Earlier in July 2026, Vivani also announced a collaboration agreement with Novo Nordisk to evaluate NPM-139 and the NanoPortal implant platform, further strengthening the development program. The company believes that continuous long-term semaglutide delivery could improve patient convenience, medication adherence, and treatment tolerability, while reducing the burden of frequent injections that often contribute to discontinuation of therapy. By combining extended drug release with the ability to reverse treatment through implant removal, the technology aims to address important limitations associated with current GLP-1 therapies for obesity and type 2 diabetes.
Advertisement
Top-Line Data Expected to Guide Phase 2 Development
Vivani Medical expects top-line Phase 1 SLIM-1 results in November 2026, which are anticipated to inform the design of a Phase 2 dose-ranging clinical trial planned for 2027. The company’s broader development strategy focuses on expanding its NanoPortal implant portfolio for chronic metabolic diseases, including obesity and type 2 diabetes, with implants intended for once- or twice-yearly administration. As GLP-1 receptor agonists continue to transform obesity treatment worldwide, Vivani aims to differentiate its platform by delivering long-acting, reversible, and highly convenient therapy that could significantly improve long-term adherence and clinical outcomes. The successful completion of participant dosing in SLIM-1 represents an important early milestone as the company advances its next-generation implant technology toward later-stage clinical development.
Source:Vivani Medical,, press release
